NVRO - NEVRO CORP ()

NVROのニュース

   Nevro to Present at Upcoming Conferences  2020/09/01 11:00:00 PR Newswire
REDWOOD CITY, Calif., Sept. 1, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present…
   Liberty All-Star® Growth Fund, Inc. July 2020 Monthly Update  2020/08/14 21:41:00 Benzinga
BOSTON , Aug. 14, 2020 /PRNewswire/ -- Below is the July 2020 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG ) Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, July, 2020 Investment Approach: Fund Style: All-Cap Growth Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund's Investment Advisor. Investment Managers: Weatherbie Capital, LLC Small-Cap Growth Congress Asset Management Company, LLP Mid-Cap Growth Sustainable Growth Advisers, LP Large-Cap Growth Top 20 Holdings at Month-End (31.0% of equity portfolio) 1 Chegg, Inc. 2.3% 2 FirstService Corp. 2.1% 3 Nevro Corp. 1.9% 4 Paylocity Holding Corp. 1.7% 5 Microsoft Corp. 1.7% 6 Visa, Inc. 1.6% 7 Facebook, Inc. 1.6% 8 Amazon.com, Inc. 1.6% 9 Progyny, Inc. 1.5% 10 Casella Waste Systems, Inc. Full story available on Benzinga.com
   Global Nerve Repair and Regeneration Market Outlook 2020: Company Profiles of Key Players Axogen, Baxter, Nevro, Nuvectra, Polyganics and Stryker - ResearchAndMarkets.com  2020/08/10 11:59:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Nerve Repair and Regeneration - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering. The Global Nerve Repair and Regeneration market accounted for $6.46 billion in 2018 and is expected to reach $21.68 billion by 2027 growing at a CAGR of 14.4% during the forecast period. Some of the key factors propelling the market growth are technological developments for nerve repair and regeneration and an increase in healthcare expense
   Nevro to Present at Canaccord Genuity 40th Annual Virtual Growth Conference  2020/08/07 11:00:00 PR Newswire
REDWOOD CITY, Calif., Aug. 7, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present…
   Why Is Nevro (NVRO) Up 7.1% Since Last Earnings Report?  2020/06/04 15:31:31 Zacks Investment Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Why Is Nevro (NVRO) Up 7.1% Since Last Earnings Report?  2020/06/04 15:31:31 Zacks Investment Research
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Nevro Appoints Finance Executive Roderick MacLeod as Chief Financial Officer  2020/06/04 11:00:00 PR Newswire
REDWOOD CITY, Calif., June 4, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Roderick ("Rod") MacLeod as Chief Financial Officer,…
   Nevro's (NVRO) Senza Omnia SCS System Gets CE Mark Approval  2020/05/18 05:59:00 Zacks Investment Research
Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.
   Nevro Announces CE Mark Approval of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain  2020/05/14 11:00:00 PR Newswire
REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received CE mark approval for the Senza® Omnia™ Spinal Cord…
   Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1  2020/05/07 13:14:00 Zacks Investment Research
Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.

calendar